ALX Oncology (NASDAQ:ALXO) is a clinical‐stage biotechnology company focused on the discovery and development of next‐generation immuno‐oncology therapeutics. The company’s lead program, ALX148, is an engineered fusion protein designed to block the CD47 “don’t eat me” signal expressed on tumor cells, with the goal of enhancing macrophage‐mediated phagocytosis in combination with checkpoint inhibitors. In addition to ALX148, ALX Oncology is advancing small‐molecule targeted protein degraders—NX-2127, a BTK (Bruton’s tyrosine kinase) degrader, and NX-1607, an IRAK4 (interleukin-1 receptor‐associated kinase 4) degrader—aimed at overcoming resistance mechanisms in hematologic and solid tumors.
Founded in 2015 and headquartered in Carlsbad, California, ALX Oncology has built a multidisciplinary team of immunologists, protein engineers, and clinical development experts. Since its inception, the company has established strategic collaborations to accelerate its programs, including partnerships with academic institutions and industry leaders to explore combination regimens and novel biomarkers. ALX Oncology’s R&D operations extend across North America, with clinical trial sites in Europe and Asia, reflecting its commitment to global patient access.
Through Phase 1 and 2 clinical studies, ALX148 has demonstrated a favorable safety profile and preliminary signs of anti‐tumor activity in patients with advanced solid malignancies and lymphoma. Meanwhile, the company’s targeted protein degraders are entering first‐in‐human trials, positioning ALX Oncology at the forefront of an emerging modality that leverages the body’s natural protein‐clearance machinery to tackle previously “undruggable” cancer targets. These assets are designed to deliver differentiated pharmacology by inducing selective degradation of disease‐causing proteins.
ALX Oncology is led by Chief Executive Officer Arnaud Chevalier, who brings over two decades of experience in oncology drug development, alongside President and Chief Medical Officer Pablo E. Castermans, M.D., and Chief Financial Officer Laura A. Alexander. The leadership team’s combined expertise in biologics, small molecules, and clinical strategy underscores the company’s mission to translate innovative science into transformative cancer therapies.
